Dr. Anika Guha is a neuroscientist and licensed clinical psychologist focused on the intersection of brain development, mental health, and substance use. She completed her undergraduate studies at Wellesley College and later received her Ph.D. in Clinical Psychology from UCLA under the mentorship of Gregory A. Miller, Ph.D., and Cindy Yee-Bradbury, Ph.D., where her NIMH-funded dissertation (F31 MH124421) used multimodal neuroimaging (fMRI and EEG) to investigate large-scale brain network dysfunction in schizophrenia. Her research identified distinct profiles of inhibitory processing abnormalities, highlighting potential intervention targets.
Following her clinical internship at the West Los Angeles VA Medical Center, Dr. Guha returned to her home state of Colorado to complete postdoctoral fellowship through the NIMH-funded Developmental Psychobiology Research Group (DPRG) program (T32 MH015442) at the University of Colorado Anschutz Medical Campus (CU Anschutz) under the mentorship of Jason Tregellas, Ph.D. There, she conducted neuroscience research utilizing a developmental framework and explored mechanisms through which interventions may potentially prevent disorder onset and reduce symptom burden.
Clinically, Dr. Guha provides psychotherapy and conducts psychosis-risk assessments using the Structured Interview for Psychosis-Risk Syndromes (SIPS), for which she was certified by the Yale Prime Clinic, in the Program for Early Assessment, Care and Study (PEACS) Clinic at CU Anschutz. Through her work in the PEACS Clinic, she works with youth and adults at clinical high risk for psychosis. Her growing clinical experience treating individuals with co-occurring cannabis use and psychosis-risk symptoms has informed her program of research and interests.
Dr. Guha recently joined the Cannabis, Health, and Addiction Over the Lifespan (CHAOS) Lab as research faculty, where her work explores the effects of cannabinoids and psychedelics on neurocognition and mental health across developmental periods, particularly adolescence and older adulthood. She recently submitted an NIMH K23 proposal to study CBD as a potential intervention for youth at clinical high risk for psychosis.